Myriad Genetics Past Earnings Performance
Past criteria checks 0/6
Myriad Genetics's earnings have been declining at an average annual rate of -50.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been declining at an average rate of 4.7% per year.
Key information
-50.4%
Earnings growth rate
-51.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -4.7% |
| Return on equity | -8.4% |
| Net Margin | -11.7% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Myriad Genetics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 661 | -77 | 444 | 83 |
| 30 Jun 22 | 672 | -18 | 494 | 81 |
| 31 Mar 22 | 682 | -8 | 502 | 80 |
| 31 Dec 21 | 691 | -27 | 538 | 82 |
| 30 Sep 21 | 684 | -57 | 599 | 80 |
| 30 Jun 21 | 662 | -97 | 542 | 78 |
| 31 Mar 21 | 566 | -148 | 514 | 76 |
| 31 Dec 20 | 557 | -224 | 501 | 73 |
| 30 Sep 20 | 598 | -194 | 499 | 74 |
| 30 Jun 20 | 639 | -199 | 507 | 77 |
| 31 Mar 20 | 761 | -148 | 539 | 81 |
| 31 Dec 19 | 813 | -26 | 546 | 83 |
| 30 Sep 19 | 835 | -15 | 547 | 86 |
| 30 Jun 19 | 851 | 5 | 557 | 86 |
| 31 Mar 19 | 830 | 23 | 512 | 83 |
| 31 Dec 18 | 796 | 26 | 479 | 80 |
| 30 Sep 18 | 767 | 54 | 451 | 74 |
| 30 Jun 18 | 744 | 133 | 435 | 71 |
| 31 Mar 18 | 749 | 130 | 444 | 72 |
| 31 Dec 17 | 763 | 126 | 459 | 71 |
| 30 Sep 17 | 771 | 101 | 472 | 73 |
| 30 Jun 17 | 729 | 17 | 440 | 74 |
| 31 Mar 17 | 757 | 32 | 446 | 75 |
| 31 Dec 16 | 751 | 63 | 414 | 75 |
| 30 Sep 16 | 748 | 94 | 385 | 73 |
| 30 Jun 16 | 741 | 117 | 359 | 71 |
| 31 Mar 16 | 757 | 121 | 349 | 70 |
| 31 Dec 15 | 747 | 108 | 349 | 69 |
Quality Earnings: MYD is currently unprofitable.
Growing Profit Margin: MYD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MYD is unprofitable, and losses have increased over the past 5 years at a rate of 50.4% per year.
Accelerating Growth: Unable to compare MYD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: MYD has a negative Return on Equity (-8.43%), as it is currently unprofitable.